Contrary to prior data, this study shows that neither eosinophils nor STAT6-mediated IL-4/IL-13 signaling contribute ...

BOSTON - Entrada Therapeutics , Inc. (NASDAQ:TRDA) received authorization from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) to initiate a Phase 1/2 clinical trial for its ...

Barbara Goodfriend, 83, opted for medical aid in dying after being diagnosed with ALS. The New Jersey widow ended her life in ...

The announcement was made at Arab Health 2025 where Sidra Medicine will highlight its international patient service programmes ...

Learn more about whether Avidity Biosciences, Inc. or TG Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Just a few weeks after Avidity Biosciences made a stir with new data on its experimental therapy for Duchenne muscular dystrophy ... component to muscle cells. Avidity is hoping to follow in ...

Top-line Phase 3 trial data show ambulatory boys with Duchenne continued with motor improvements two years after a single ...

Potent in vivo gene editing in skeletal muscle of non-human primates by a novel, ultracompact CRISPR system delivered via a single AAV vector.

Sarepta Therapeutics has followed through on its promise to file for accelerated approval of its gene therapy SRP-9001 for Duchenne muscular ... that helps keep muscle cells intact.

It was the type of upsetting yet commonplace problem most parents face from time to time. Early last month, the Taylor family were on their way home from a meal out when Trey, 11, began feeling sick.

Personalized organoids — ‘mini-organs’ — may accelerate treatment for patients with rare genetic disorders. Courtesy of Europeana via Unsplash Across the globe, countless babies ...